A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study

Abstract

Get full access to this article

View all access options for this article.

References

National diabetes statistics report, 2017. Accessed March 10, 2019. https://dev.diabetes.org/sites/default/files/2019-06/cdc-statistics-report-2017.pdf

American Diabetes Association. Standards of medical care in diabetes — 2020. Diabetes Care. 2020;43(Suppl. 1):S1-S212.

Secrest

Udell

Filion

KB.

The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. Trends Cardiovasc Med. 2017;27:194-202.

Mellbin

Wang

Rydén

Clinical implications of cardiovascular outcome trials in type 2 diabetes. Herz. 2019;44:192-202.

Hussein

Zaccardi

Khunti

Seidu

Davies

Gray

LJ.

Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabet Med. 2019;36:444-452.

Davies

Pham

Drab

SR.

GLP1-RA add-on therapy in patients with type 2 diabetes currently on a bolus containing insulin regimen. Pharmacotherapy. 2016;36:893-905.

Ofstad

Atar

Gullestad

Langslet

Johansen

OE.

The heart failure burden of type 2 diabetes mellitus — a review of pathophysiology and interventions. Heart Fail Rev. 2018;23:303-323.

Wiviott

Raz

Bonaca

, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-357.

Gerstein

Colhoun

Dagenais

, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121-130.

10.

Zinman

Wanner

Lachin

, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.

11.

Neal

Perkovic

Mahaffey

, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.

12.

Pantalone

Misra-Hebert

Hobbs

, et al. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2018;17:54.

13.

Adams

Weaver

KK.

The continuum of pharmacist prescriptive authority. Ann Pharmacother. 2016;50:778-784.

14.

Gentry

Parker

Ketel

, et al. Integration of clinical pharmacist services into an underserved primary care clinic utilizing an interprofessional collaborative practice model. J Health Care Poor Underserved. 2016;27:1-7.

15.

Alfayez

Al Yami

Fazel

MT.

The impact of pharmacists providing direct patient care as members of interprofessional teams on diabetes management. Saudi Pharm J. 2017;25:1019-1021.

16.

Bukhsh

Tan

Chan

Lee

L-H

Goh

B-H

Khan

TM.

Effectiveness of pharmacist-led educational interventions on self-care activities and glycemic control of type 2 diabetes patients: a systematic review and meta-analysis. Patient Pref Adherence. 2018;12:2457-2474.

17.

Presley

Groot

Pavlova

Pharmacy-led interventions to improve medication adherence among adults with diabetes: a systematic review and meta-analysis. Res Social Adm Pharm. 2019;15:1057-1067.

18.

Meade

Tart

Buzby

HL.

Evaluation of diabetes education and pharmacist interventions in a rural, primary care setting. Diabetes Spectr. 2018;31:90-95.

19.

Pitlick

Brooks

AD.

Glycemic control in pharmacist-managed insulin titration versus standard care in an indigent population. Diabetes Spectr. 2011;24:211-217.

20.

Stading

Herrmann

Walters

Destache

Chock

Impact of pharmacist intervention on diabetes patients in an ambulatory setting. Diabetes Spectr. 2009;22:241-246.

21.

Ramser

Sprabery

George

, et al. Physician-pharmacist collaboration in the management of patients with diabetes resistant to usual care. Diabetes Spectr. 2008;21:209-214.

22.

Trulicity [package insert]. Eli Lilly & Co, 2017

23.

Gerstein

Miller

Byington

, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.

24.

Yancy

Jessup

Bozkurt

, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137-e161.

25.

Gulati

Udelson

JE.

Heart failure with improved ejection fraction: is it possible to escape one’s past?

JACC Heart Fail. 2018;6:725-733.

26.

McMurray

JJV

Solomon

Inzucchi

, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008.

27.

Greene

Butler

Albert

, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351-366.

28.

Whelton

Carey

Aronow

, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-e115.

29.

Grundy

Stone

Bailey

, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-e1143.

30.

Jacobson

Ito

Maki

, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 — full report. J Clin Lipidol. 2015;9:129-169.

31.

ISMP list of high-alert medications in community/ambulatory healthcare. 2011. Accessed April 20, 2020. https://www.ismp.org/sites/default/files/attachments/2017-11/highAlert-community.pdf

32.

ISMP guidelines for optimizing safe subcutaneous insulin use in adults. 2017. Accessed March 10, 2019. https://www.ismp.org/sites/default/files/attachments/2017-11/ISMP138-Insulin%20Guideline-051517-2-WEB.pdf